Keywords: Apricus Biosciences, Funding Frency units, Vitaros, Femprox, Scomedica, NexMed
Apricus to stop funding French units; will focus on Vitaros and Femprox
Article | 14 March 2013
USA-based Apricus Biosciences (Nasdaq: APRI) says that it intends to cease financing its French subsidiaries, Finesco, its French holding company, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
